OncoMatch/Clinical Trials/NCT05053867
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
Is NCT05053867 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies tranexamic acid for pulmonary hemorrhage.
Treatment: tranexamic acid — This is a drug study that will examine if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: inhaled tranexamic acid
Cannot have received: anti-fibrinolytic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05053867 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior inhaled tranexamic acid, anti-fibrinolytic therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify